- Home
- QURE vs GHRS Comparison
QURE vs GHRS Comparison
Compare QURE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | GHRS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Netherlands | Ireland |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QURE | GHRS |
|---|---|---|
| Price | $27.85 | $24.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $45.00 | $41.38 |
| AVG Volume (30 Days) | ★ 1.9M | 204.4K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $10.96 |
| 52 Week High | $71.50 | $24.66 |
Technical Indicators
Market Signals| Indicator | QURE | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 66.60 |
| Support Level | $20.20 | $12.65 |
| Resistance Level | $29.03 | $24.66 |
| Average True Range (ATR) | 1.74 | 1.55 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 75.56 | 92.71 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.